Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
2007 Feb 09
Journal Article
Authors:
Parrino, J.;
McCurdy, L.H.;
Larkin, B.D.;
Gordon, I.J.;
Rucker, S.E.;
Enama, M.E.;
Koup, R.A.;
Roederer, M.;
Bailer, R.T.;
Moodie, Z.;
Gu, L.;
Yan, L.;
Graham, B.S.
Secondary:
Vaccine
Volume:
25
Pagination:
1513-25
Issue:
8
PMID:
17126963
DOI:
10.1016/j.vaccine.2006.10.047
Keywords:
Adolescent; Adult; Antibody Formation; CD8-Positive T-Lymphocytes; Double-Blind Method; Humans; Middle Aged; Smallpox; Smallpox Vaccine; Vaccinia virus
Abstract:
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
